Quality of Life in Gynecologic Cancer Survivors Compared to Healthy Check-up Women
Overview
Oncology
Authors
Affiliations
Objective: The primary objective of this study was to compare quality of life of disease-free patients after therapy for gynecologic malignancies at follow-up in comparison with healthy check-up patients. Our second objective was to assess correlation between demographic data, disease and treatment factors and quality of life scores.
Methods: Patients completed the Functional Assessment of Cancer Therapy-General (FACT-G) quality of life questionnaire at least 6 months after treatment for a gynecologic malignancy. Responses were compared to unmatched healthy women who were seen for standard gynecologic screening examinations. Statistical calculation was done using chi-squared tests, Wilcoxon rank-sum, and Kruskal-Wallis one-way analysis and Spearman rank correlations. Factors associated with FACT-G scores were evaluated using univariate and multivariate analyses.
Results: Eight hundred and seventy patients were recruited. The median time since therapy was 61 months (range, 6 to 173 months). The overall FACT-G scores were higher in the patient group than in the healthy group (p<0.05). The scores of each subscale measuring physical, functional, social/family and emotional well-being were also higher in the patient group (p<0.05). Multivariate analysis revealed correlation between Eastern Cooperative Oncology Group performance status, educational level, care giver, presence of economic problems and FACT-G scores.
Conclusion: The quality of life scores were higher in gynecologic cancer patients after treatment. And the factors that associated with the higher score in the patient group are having husband as a caregiver, no financial problem, Eastern Cooperative Oncology Group score 0 or 1 and having high school or higher education.
Kim J, Kim Y, Oh J, Lee S Sci Rep. 2024; 14(1):9876.
PMID: 38684776 PMC: 11059168. DOI: 10.1038/s41598-024-60710-6.
Kim S, Noh J, Kim Y, Cho J, Kang D, Lee Y Cancer Med. 2024; 13(5):e7096.
PMID: 38466031 PMC: 10926879. DOI: 10.1002/cam4.7096.
Jetan M, Daifallah A, Rabayaa M, Qadri R, Nassorah M, Nouri A Integr Cancer Ther. 2023; 22:15347354231210841.
PMID: 37961876 PMC: 10647945. DOI: 10.1177/15347354231210841.
Gounitsioti I, Poulimeneas D, Grammatikopoulou M, Kotzamanidis C, Gkiouras K, Nigdelis M Int J Environ Res Public Health. 2022; 19(16).
PMID: 36011958 PMC: 9408329. DOI: 10.3390/ijerph191610322.
Surviving and thriving: What do survivors of gynecologic cancer want?.
Peerenboom R, Ackroyd S, Chang C, Moore E, Vogel T, Lippitt M Gynecol Oncol Rep. 2022; 41:101011.
PMID: 35663850 PMC: 9160655. DOI: 10.1016/j.gore.2022.101011.